Abstract. The family of Wnt proteins have been implicated in embryogenesis by regulation of cell fate and pattern formation, and also in human carcinogenesis. Wnt10B was previously shown to be involved in breast cancer development. The present study assessed the association of Wnt10B expression in human gastric cancer tissue specimens with clinicopathological data from these patients. Wnt10B expression in the regulation of gastric cancer cell proliferation and migration capacity in vitro was then investigated. The data revealed that Wnt10B mRNA and protein were upregulated in gastric cancer tissue samples and the upregulated Wnt10B mRNA was associated with gastric cancer metastasizing to lymph nodes. Knockdown of Wnt10B expression reduced gastric cancer cell proliferation and migration, as well as expression of a cell proliferation marker Ki67. Knockdown of Wnt10B expression inhibited tumor cell epithelial-mesenchymal transition by upregulation of E-cadherin and downregulation of N-cadherin. In addition, Wnt10B knockdown also suppressed tumor cell stemness by downregulation of octamer-binding transcription factor 4 and Nanog expression. The present data indicated that Wnt10B expression performs an important role in gastric cancer progression in vitro. Therefore, targeting of Wnt10B expression or activity may be investigated as a possible strategy for the control of gastric cancer.
Introduction
Gastric cancer is the second most common cancer in the world, accounting for one million cancer-associated mortalities annually and representing a major worldwide public health problem (1) . With advances in early detection, standardized surgical treatment and improved perioperative care, the outcomes of patients with gastric cancer have notably improved (2) . However, diagnosis of gastric cancer at early stages remains a challenge in clinical settings due to asymptomatic or nonspecific symptoms in early lesions, as well as lack of effective biomarkers. Gastric cancer development and progression involves multiple factors (3) . Helicobacter pylori infection is a major risk factor in gastric cancer development (4) . Tobacco smoke, alcohol consumption and dietary factors, including smoked foods, salt-rich foods, red meat and pickled vegetables are also associated with increased gastric cancer incidence (5) . These factors potentially involve chronic inflammation and gastric carcinogenesis (5) . Over the past decades, efforts have been made to elucidate the underlying mechanisms and to identify novel diagnostic biomarkers and therapeutic targets for gastric cancer. However, gastric cancer mortality remains high (6) . Therefore, additional investigation and attention is required to identify novel biomarkers for early diagnosis, prognosis and treatment response prediction of gastric cancer and/or to identify novel targets to control gastric cancer.
Nusse and Varmus identified the first member of the Wnt gene family in 1982 (7) , and it is now well accepted that these highly conserved Wnt secreted proteins are critical mediators of cell-to-cell signaling, cell fate and pattern formation during embryonic development. The Wnt family of proteins includes at least 19 secreted-type glycoproteins with 22-24 conserved cysteine residues (8) . This canonical Wnt pathway regulates target gene expression in the nucleus to control cell proliferation (9) , and the non-canonical pathways regulate numerous other aspects of cell biology, including cell motility and morphology (10) . Altered expression of Wnt gene family proteins is associated with human carcinogenesis (7) . In gastric cancer, Wnt signaling may promote self-renewal of gastric cancer stem cells (CSCs); therefore, targeting of Wnt signaling may lead to a clinical gastric cancer therapy (11) . Wnt10B, localized on human chromosome 12q13 (12) , was implicated in cancer development and progression by regulating nuclear factor-κB and Notch pathways in osteosarcoma cells (13) . However, Wnt10B is a bi-functional protein; one function involves β-catenin/transcription factor activation to promote tumor progression and the second function is associated with downregulating cell growth through a β-catenin-independent mechanism (14) . In the present study, the association between Wnt10B mRNA and protein levels in human gastric cancer Wnt10B is critical for the progression of gastric cancer XIAO To induce shRNA expression, the cells were treated with 80 µg/ml doxycycline (Sigma-Aldrich: EMD Millipore) and the efficiency of Wnt10B knockdown was assessed by RT-qPCR and western blot analysis.
RNA isolation and RT-qPCR. Total RNA was isolated from tissues and cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) and 2 µl aliquots of RNA samples were reversely transcribed into cDNA using a HiScript 1st strand cDNA synthesis kit (Vazyme, Piscataway, NJ, USA) according to the manufacturer's protocol. The qPCR amplifications were performed using the QuantiTect SYBR-Green PCR kit (Toyobo Co., Ltd., Osaka, Japan) according to the manufacturer's protocol. Thermal cycle parameters were as follows: 95˚C for 5 min; 40 cycles at 95˚C for 30 sec, 60˚C for 30 sec, and 72˚C for 30 sec; and 65-95˚C drawing dissociation curve. β-actin was used as an internal control. The expression of each gene was defined from the threshold cycle (Cq) and the melting temperatures were recorded. Using the 2 -ΔΔCq method (15), relative changes in mRNA expression were analyzed. The sequences of specific primers are presented in Table I .
Protein extraction and western blot analysis. Tissues and cells
were homogenized and lysed in radioimmunoprecipitation assay buffer supplemented with proteinase inhibitors (1 mM nphenylmethanesulfonyl fluoride; Vazyme, Piscataway, NJ, USA). The protein concentration of each sample was determined by the bicinchoninic acid protein assay kit (CWBIO, Beijing, China). Equal amounts of protein were subjected to SDS-PAGE on 12% SDS-PAGE gels and then transferred to polyvinylidene difluoride membranes. For western blot analysis, the membrane was blocked in 5% (w/v) skim milk for 1 h at 37˚C and incubated with a primary antibody for 12 h at 4˚C, followed by a horseradish peroxidase-conjugated anti-rabbit secondary antibody (#AP188P; EMD Millipore) for 1 h at 37˚C. Protein bands were detected by the enhanced chemiluminescence detection system (GE Healthcare Life Sciences, Chalfont, UK). The primary antibodies used were: Anti-Wnt10B (dilution, 1:200; sc-25524; Santa Cruz Biotechnology, Inc., Dallas, TX, USA); GAPDH (dilution, 1:2,000; #CW0100A; Kangcheng Pharmaceutical Co. Ltd., Guangzhou, China); Ki67 (dilution, 1:1,000; #9449; Cell Signaling Technology, Inc., Danvers, MA, USA); β-catenin (dilution, 1:1,000; #8480; Cell Signaling Technology, Inc.); cyclin D1 (dilution, 1:500; #P24385; Bioworld Technology, Inc., St. Louis Park, MN, USA); N-cadherin (dilution, 1:1,000; #13116; Cell Signaling Technology, Inc.); E-cadherin (dilution, 1:1,000; #14472; Cell Signaling Technology, Inc.); octamer-binding transcription factor 4 (Oct4; dilution, 1:200; #sc-365509; Santa Cruz Biotechnology, Inc.); and Nanog antibody (dilution, 1:200; #25045; Signalway Antibody, Danvers, MA, USA).
Immunofluorescence. Tissue samples or cells were fixed in 4% paraformaldehyde for 20 min, permeabilized for 3 min with 0.1% Triton X-100, and blocked with 5% bovine serum albumin for 20 min. The sections were then incubated with indicated aforementioned primary antibodies overnight at 4˚C, followed by incubation with Cy3-labeled anti-mice IgG secondary antibody at a dilution of 1:800 (#CW0145; Kangcheng Pharmaceutical Co. Ltd.), at 37˚C for 45 min. The nuclei were then counterstained with DAPI (Sigma-Aldrich, EMD Millipore). The sections were reviewed under a fluorescent microscope (Nikon, Tokyo, Japan) and images were sequentially captured for evaluation.
Cell counting assay. Cells were seeded at a density of 1x10 4 cells per well onto 24-well plates and grown for up to 4 days. The cells were cultured at 37˚C in humidified air containing 5% CO 2 . At the end of each experiment, the cells were collected and counted in triplicate for each group at the indicated time points (0, 1, 3 and 4 days). The data were summarized as a percentage of the control.
Tumor cell wound healing assay. Cells were seeded at a density of 5x10 5 cells per well onto 6-well plates and incubated for ~24 h at 37˚C to reach >95% confluency of the monolayer. Wounds were then created using a sterile plastic micropipette tip on the cell monolayer and the plates were washed with PBS twice and 37˚C cultured for an additional 24 h. Images of the cells were captured at 0 and 24 h to measure the wound healing for five randomly selected fields. The width of wound healing at the original scratches was measured and calculated using NIH Image version 1.62 program (http://rsb.info.nih. gov/nih-image/). The data are expressed as the mean ± standard deviation and presented as a percentage of the control.
Tumor cell Transwell migration assay. SGC-7901 cells were seeded at a density of 1x10 5 per well into the upper chamber of a 6.5 mm Transwell insert (#3422; Corning Incorporated, Corning, NY, USA). DMEM supplemented with 10% FBS was added into the bottom chamber and the cells were incubated at 37˚C for 16 h. At the end of the experiment, cells remaining on the membrane surface were removed with cotton swabs and cells that had migrated through the membrane (pore size, 8 mm) were fixed with 4% paraformaldehyde, stained for 15 min at room temperature with 1% crystal violet (Sigma-Aldrich; EMD Millipore), and images were captured by light microscope (Nikon, Tokyo, Japan).
Statistical analysis. Differences in the expression of Wnt10B mRNA in paired tumor and normal tissues was analyzed by the Mann-Whitney U test with GraphPad Prism 5.0 software (GraphPad Software, La Jolla, CA, USA). Association between Wnt10B expression and clinicopathological factors was estimated by Fisher's exact test. Statistically significant correlation between two continuous variables was analyzed by the Spearman's rho test. The statistical association between two groups was analyzed by Student's t-test. P<0.05 was considered to indicate a statistically significant difference.
Results
Upregulated Wnt10B mRNA is associated with lymph node metastasis of gastric cancer. To assess the potential role of Wnt10B in gastric cancer, RT-qPCR analysis of Wnt10B was performed in 25 pairs of gastric cancer and adjacent normal tissues. Levels of Wnt10B mRNA in gastric cancer tissues were significantly higher compared with the paired adjacent normal tissues (P<0.001; Fig. 1A and B) . Western blotting and immunofluorescence were then performed to analyze the expression of Wnt10B protein in these samples, and it was identified that levels of Wnt10B protein were also increased in gastric cancer tissues (Fig. 1C and D) .
It was then determined whether associations exist between Wnt10B mRNA level and clinicopathological characteristics of patients. High levels of Wnt10B were revealed to be associated with lymph node metastasis (P=0.022; Table II), but no associations were observed with other clinicopathological characteristics, including age, gender, tumor size, histological grade or clinical stages. 
Wnt10B knockdown inhibits gastric cancer cell proliferation and migration in vitro.
Wnt10B expression was knocked down in gastric cancer SGC-7901 cells using lentivirus carrying Wnt10B shRNA. Wnt10B shRNA significantly reduced levels of Wnt10B mRNA and protein in the Wnt10B shRNA-infected (shWnt10B) SGC-7901 cells compared with the negative control shRNA (P<0.001; Fig. 2A and B) . In addition, knockdown of Wnt10B expression inhibited gastric cancer proliferation compared with the control shRNA-infected gastric cancer cells (Fig. 2C ). Ki67 immunofluorescent-staining and western blot analysis data confirmed that Wnt10B shRNA reduced tumor cell proliferation ( Fig. 2D and E) . The role of Wnt10B in regulation of gastric cancer cell motility was assessed using wound healing and Transwell migration assays. Wnt10B knockdown markedly reduced gastric cancer cell wound healing and migration capacity compared with the controls (Fig. 2F and G) .
Knockdown of Wnt10B expression inhibits the Wnt/β-catenin signaling pathway and cancer cell stemness.
A number of previous studies demonstrated that activation of the Wnt/β-catenin signaling pathway was able to induce epithelial-mesenchymal transition (EMT) of cells and acquire cell stemness (12, (16) (17) (18) (19) . Thus, the present study confirmed the effects of Wnt10B knockdown on gastric cancer cells, and it was identified that Wnt10B knockdown reduced expression of β-catenin and the targeting gene cyclin D1 in SGC-7901 cells (Fig. 3A) . The expression of the epithelial cell marker E-cadherin was upregulated, whereas expression of the mesenchymal cell marker N-cadherin was downregulated (Fig. 3A and B) , indicating a reversed EMT phenomenon in gastric cancer cells. Subsequently, expression of the stem cell markers Oct4 and Nanog was detected in the Wnt10B knocked down cells. Expression of Oct4 and Nanog proteins was decreased in Wnt10B knocked down cells compared with the control cells (Fig. 3C) . Therefore, it was speculated that Wnt10B may increase the number of stem cells in gastric cancer tissue. Thus, the Wnt10B mRNA and stem cell markers Oct4 and Nanog mRNA were detected in gastric cancer tissues by real-time RT-PCR, and the association between Wnt10B, Oct4 and Nanog was analyzed. The results demonstrated that there was a positive correlation between Wnt10B and Oct4 (r=0.8033), and Wnt10B and Nanog (r=0.7630) in gastric cancer tissues (Fig. 3D) .
Discussion
One hallmark of tumor biology is activation of the canonical Wnt pathway and upregulated stability and nuclear localization of β-catenin to promote expression of targeted genes during human tumorigenesis or development (20) (21) (22) . Upregulation of Wnt/β-catenin signaling can enhance EMT in different types of cancer cells, including prostate, hepatocellular and gastric cancer cells (16) (17) (18) (19) , as well as proliferation and formation of CSCs (11, 23) . The present study first analyzed the association of Wnt10B expression in human gastric cancer tissues with clinicopathological data from patients, and then investigated the role of Wnt10B in the regulation of gastric cancer cell proliferation and migration, and the underlying molecular events in vitro. The present data demonstrated that Wnt10B mRNA and protein were upregulated in gastric cancer tissues compared with the paired normal tissues. The upregulated Wnt10B expression was associated with gastric cancer metastasizing to lymph nodes. In addition, knockdown of Wnt10B expression reduced gastric cancer cell proliferation and migration and expression of Ki67 protein. Knockdown of Wnt10B expression also inhibited tumor cell EMT by upregulating E-cadherin and downregulating N-cadherin and tumor cell stemness, via downregulation of Oct4 and Nanog expression. The data from the present study indicated that knockdown of Wnt10B expression may have a role in suppressing gastric cancer progression. Additional studies are required to investigate whether targeting Wnt10B expression or activity may be a novel strategy to control gastric cancer.
Wnt10B, a member of the Wnt family of proteins (24), is conserved among diverse species and serves a crucial role in normal tissue development (25, 26) . A previous study revealed that Wnt10B activates canonical β-catenin signaling to promote development of breast cancer (27) . It was also suggested that Wnt10B is expressed differently in benign and malignant diseases, and has the potential to be a tumor biomarker in molecular diagnosis of human cancer (28) . In the present study, the usefulness of detection of Wnt10B expression to differentiate normal tissues from tumor tissues was confirmed. In addition, the present data also revealed that Wnt10B expression is associated with gastric cancer lymph node metastasis, indicating that Wnt10B is not only altered early in gastric cancer development, but is also associated with gastric cancer progression. Additional studies with a larger sample size are required to confirm the present data.
Furthermore, the present data demonstrated that knockdown of Wnt10B expression inhibits proliferation and migration of gastric cancer cells. It is widely accepted that cancer metastasis is one of the malignant properties of cancer and the main cause of cancer-associated mortality (29) . Wnt10B-associated tumor cell migration and wound healing may promote gastric cancer progression. Phenotypically, tumor cell EMT is an important process in cancer development and metastasis (30) . When cancer cells acquire EMT phenotypes, they invade the surrounding tissue and eventually metastasize to distant sites (31) . The present study showed that knockdown of Wnt10B inhibits migration of gastric cancer cells via suppression of tumor cell EMT. This is evident by enhanced expression of the epithelial marker E-cadherin, but reduced expression of mesenchymal marker N-cadherin in gastric cancer cells.
In addition, CSCs have been identified in a variety of human cancers, such as breast, brain, prostate, melanoma, colon, liver, pancreatic and head and neck cancer, and are able to initiate tumorigenesis and cause tumor metastasis (32) . A previous study demonstrated that activation of the Wnt/β-catenin pathway in cancer cells induces their stem cell characteristics (33) . The stem cell markers Oct4, sex-determining region Y-box 2, Nanog and Krüppel-like factor 4 are important target genes of the Wnt/β-catenin pathway (34) . In the present study, it was identified that Wnt10B level was positively associated with stem cell markers in gastric cancer tissues, supporting that Wnt10B may be involved in the generation and maintenance of CSCs in gastric cancer. These data were also confirmed in Wnt10B knockdown cells, demonstrating that reduced Wnt10B expression also downregulated expression of Oct4 and Nanog in gastric cancer cells in vitro. Further studies P<0.01 and *** may confirm whether Wnt10B knockdown inhibits β-catenin translocation into cell nuclei, as shown by previous studies in other cancers (35) (36) (37) (38) .
The present study provides proof-of-principle, demonstrating that alteration in Wnt10B expression is associated with gastric cancer. Future studies may confirm the effects of Wnt10B in gastric cancer to provide a novel diagnostic and prognostic biomarker for gastric cancer and a therapeutic strategy to control gastric cancer. In addition, the mechanisms responsible for the aberrant expression of Wnt10B in gastric cancer will also be investigated. Furthermore, the authors will perform animal experiments to verify the effects of Wnt10B knockdown in suppression of gastric cancer metastasis.
